Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 278

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1B
Chunk 278
---
9, by and between DOT Therapeutics-1, Inc. and Millennium Pharmaceuticals, Inc.
     
    S-1
     
    333-255754
     
    May 4, 2021

    10.8†
     
    License Agreement for RAF, effective as of December 16, 2019, by and between Sunesis Pharmaceuticals, Inc. and DOT Therapeutics-1, Inc.
     
    S-1
     
    333-255754
     
    May 4, 2021

    10.9†
     
    License Agreement, dated February 10, 2021, by and between Merck KGaA, Darmstadt, Germany and Day One Biopharmaceuticals, Inc.
     
    S-1
     
    333-255754
     
    May 4, 2021

    10.10
     
    Stock Exchange Agreement, dated May 4, 2021, by and between Day One Biopharmaceuticals Holding Co., LLC and Millennium Pharmaceuticals, Inc.
     
    S-1
     
    333-255754
     
    May 4, 2021

    10.11†
     
    Amendment No. 1 to the License Agreement for RAF, dated March 4, 2024, by and between Day One Biopharmaceuticals, Inc. and Sunesis Pharmaceuticals, Inc.
     
    8-K
     
    001-40431
     
    March 7, 2024

    10.12†*
     
    Asset Purchase Agreement, dated May 29, 2024.
     
    10-Q
     
    001-40431
     
    August 2, 2024

    10.13†*
     
    Exclusive License Agreement by and between MabCare Therapeutics and Day One Biopharmaceuticals, Inc. dated June 17, 2024. 
     
    10-Q
     
    001-40431
     
    August 2, 2024

    10.14†*
     
    Exclusive License Agreement by and between Day One Biopharmaceuticals, Inc. and Ipsen Pharma SAS dated July 23, 2024.
     
    10-Q 
     
    001-40431
     
    October 30, 2024

    19.1